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Some medical diagnostic and therapeutic interventions are non-beneficial or even harmful. The 
Choosing Wisely campaign has encouraged the generation of “top five” lists of unnecessary low-value 
services in different specialist areas. In the USA alone, where the campaign was launched, these lists 
include a total of 450 evidence-based recommendations. Professional associations in further countries 
such as Canada, Australia, New Zealand, England, Switzerland and Germany have since initiated 
Choosing Wisely campaigns. Besides implementing top five lists, these aim to change attitudes, 
expectations and practices in the culture of medicine. The field of internal medicine has spearheaded 
change in Switzerland (Swiss Society of General Internal Medicine: Smarter Medicine) and Germany 
(German Society of Internal Medicine: Klug entscheiden). Formulating Choosing Wisely principles in 
managing complex patients with multiple concurrent acute or chronic diseases, i.e., multimorbidity 
(MM), will present a particular challenge. Research is needed to determine the primary sources of 
overuse in specific combinations of diseases (i.e., MM clusters) and spearhead corresponding 






Einige medizinische diagnostische und therapeutische Interventionen sind nicht vorteilhaft oder 
sogar schädlich. Choosing Wisely Kampagnen haben die Erstellung von "Top-5" -Listen unnötiger 
oder minderwertiger Interventionen (Low-Value-Services) in verschiedenen Fachgebieten gefördert. 
Allein in den USA, wo die Kampagne gestartet wurde, enthalten diese Listen insgesamt 450 
evidenzbasierte Empfehlungen. Berufsverbände in weiteren Ländern wie Kanada, Australien, Neu 
Seeland, England, der Schweiz und Deutschland haben seitdem Choosing Wisely Kampagnen initiiert. 
Neben der Implementierung von Top-5-Listen sollen diese Einstellungen, Erwartungen und Praktiken 
in der Kultur der Medizin verändern. Wissenschaftliche Fachverbände der Inneren Medizin haben in 
der Schweiz (Schweizerische Gesellschaft für Allgemeine Innere Medizin: Smarter Medicine) und in 
Deutschland (Deutsche Gesellschaft für Innere Medizin: Klug entscheiden) Choosing Wisely 
Kampagnen vorangetrieben. Das Formulieren von Choosing Wisely Kampagnen bei der Betreuung 
komplexer Patienten mit mehreren gleichzeitigen akuten oder chronischen Krankheiten, d.h. 
Multimorbidität (MM), wird eine besondere Herausforderung darstellen. Forschung ist erforderlich, 
um die primären Quellen der Überbeanspruchung in bestimmten Kombinationen von Krankheiten 
(d.h. MM-Cluster) und entsprechende Empfehlungen zu entwickeln. Nationale Choosing Wisely 




The beginnings of Choosing Wisely 
 
Modern medicine has produced an impressive range of diagnostic and therapeutic interventions.1,2 
Careful evaluation of their effectiveness suggests that some of these interventions have no 
recognizable benefit and can even be detrimental to the patient.3,4,5 While acting in good faith, 
clinicians and their institutions may be unwittingly promoting overuse of health care resources, 
without adding value of care for patients, by delivering ineffective, harmful wasteful or unnecessary 
interventions.6,7 This problem is estimated to account for as much as 30% of all medical expenditure 
in the USA.8,9 
Information to discourage the use of non-beneficial or harmful interventions may be collected from a 
wide variety of sources. However, high-quality knowledge in medical databases can be difficult to 
access and knit together for specific cases. Also, medical books are limited to generic principles and 
can soon become outdated. Online databases of medical research are growing so quickly that the sheer 
quantity of information can hinder the capacity of individuals to retrieve, process and use new 
knowledge to guide treatment decisions.10,11 Systematic literature reviews often focus on favorable 
findings of effectiveness with little mention of safety and tolerability,12,13 and the all too literal 
application of clinical guidelines may be wrong or even hazardous for the individual patient.14  
 
The over- and underuse of medical resources has long been the subject of debate in expert 
committees, specialist associations, professional and non-specialist media, governmental and non-
governmental organizations, and the general public.15,16  But this debate has been hard to initiate, to 
maintain and to apply. This is in part because research has focused more on underuse of health care. 
Furthermore, development of measures of overuse has met with various research, cultural, and 
political challenges,17 and because efforts to bring the various stakeholders together has been slow.18 
Therefore, the American Board of Internal Medicine (ABIM) Foundation started Choosing Wisely in 
2012 to encourage physicians and patients in the USA to enter into dialogue about overuse of 





Choosing Wisely invited a diverse array of specialist societies to determine in their own field of 
expertise a “top five” list of particularly prevalent low-value services. These lists have the character of 
recommendations based on evidence of inappropriate and potential harm. This medical campaign has 
been a great success. To date, over 60 medical societies in the USA have created a total of 450 
recommendations through lists of five common tests, treatments or procedures for which there is 
strong scientific evidence that they do not benefit patients or may even cause harm.12,13 Wisely Canada 
followed USA in 2014, with 21 societies, and supporting patient organizations, generating top five 
recommendations within two years 23,24,25 and a total of 264 recommendations. 26 Choosing Wisely 
Australia27 began in 2015, with 21 societies generating by the end of 2016 a total of 123 
recommendations.  
 
Professional associations in further countries, including New Zealand, England, Wales, Japan, Italy, 
Holland, Denmark, Switzerland and Germany have since launched Choosing Wisely campaigns to reach 
and influence the professional field.28 Choosing Wisely in the UK can build on the work of the National 
institute for health and Care Excellence (NICE) that has identified around 800 potentially unnecessary 
interventions.29 Besides the top five lists, the key elements of the Choosing Widely campaigns relate 
to changing physician attitudes to practice, patient engagement and acceptance, key clinical practices 
(e.g., shared decision making), and better alignment with the healthcare system (e.g., with the 
payment system). 30,31,32,33 Generally, these campaigns differ in stage of implementation,34 
sponsorship, structure, methods, organization, financing, and content. For example, the German 
initiative (Klug Entscheiden) considers both overuse and as well as underuse of beneficial procedures, 
having now generated 115 recommendations through 12 specialist societies and actively disseminated 
these in specialist literature.35 
 
 
Smarter Medicine  
 
The campaign in Switzerland, referred to as Smarter Medicine, has been spearheaded by experts and 
chief physicians in the field of internal medicine by the Swiss Society of General Internal Medicine 
(Schweizerische Gesellschaft für Allgemeine Innere Medizin), focussing on low-value and especially 
prevalent interventions for outpatients in 2014 and for inpatients in 2016.36,37   
These recommendations could be taken as a general example of the style of recommendations of 
societies in Choosing Wisely campaigns. Thus, the Swiss campaign outlined five procedures to be 
avoided for outpatients:  
1. Obtaining imaging studies during the first six weeks in patients with non-specific low back 
pain. 
2. Performing the Prostate Specific Antigen (PSA) test to screen for prostate cancer without 
a discussion of the risks and benefits. 
3. Prescribing antibiotics for uncomplicated upper respiratory tract infections. 
4. Obtaining preoperative chest radiography in the absence of a clinical suspicion for intra- 
thoracic pathology. 
5. Continuing long-term treatment of gastro-intestinal symptoms with proton pump inhibitors 
without titrating to the lowest effective dose needed. 
For inpatients, procedures to be avoided include:  
1. Ordering blood tests at regular intervals or routine extensive lab panels including X-rays without 
specific clinical questions. 
2. Placing or leaving in place urinary catheters for incontinence or monitoring of output for non-
critically ill patients.  
3. Transfusing more than the minimum number of red blood (RBC) units necessary to relieve 
symptoms of anemia or to return a patient to a safe hemoglobin range. 
4. Letting older adults lie in bed during their hospital stay. In addition, individual therapeutic goals 
should be established considering the patients’ values and preferences. 
5. Using benzodiazepines or other sedative-hypnotics in older adults as first choice for insomnia, 
agitation or delirium and avoid prescription at discharge.  
 
Choosing Wisely and multimorbidity 
  
When recommendations from top-five lists are not relevant for a specific case, Choosing Wisely 
encourages prudent judgement as to what the clinician and patient should or should not do in order 
to counter overuse. For example, avoiding imaging studies in patients with “non-specific low back pain” 
(the first Swiss recommendation for outpatients) asks for very careful clinical evaluation to identify 
“specific low back-pain” and the identification of “red flags”, i.e., symptoms or signs, that would 
support immediate use of imaging studies. 38 Such red flags in back pain also include morbidities such 
as immunosuppression, cancer and tumors and inflammatory diseases which may suggest a more 
severe, complicated or dangerous disease constellation. For example, a patient with kidney 
transplantation and therefore immunosuppression may develop back pain due to spondylodiscitis, i.e., 
he may have two or more concurring disease conditions. Judgements are therefore inherently tied to 
the particulars of the unique patient, especially when handling multiple concurrent acute or chronic 
diseases, that is, multimorbidity (MM).39,40 In MM, the clinician is often faced with complex trade-offs 
between benefits and risks of different treatment strategies in order to manage potentially adverse 
disease-disease, drug-disease and drug-drug interactions (DDIs).41 Instead of there being a “right” 
treatment, the clinician prioritizes and reconciles these DDIs with the most suitable therapeutic 
strategy for the patient’s specific pattern of diseases, goals and preferences.42 Recommendations from 
clinical practice guidelines and the top-five lists could enhance uncertainties,43 as these typically relate 
to the treatment of single diseases (with exceptions, e.g.,44,45,46). The handling of multiple uncertainties 
can in itself lead to overuse, for example, by over-precautionary use of tests and treatments in order 
to diminish potential risks to patients and enhance subjective confidence in the selected course of 
treatment.47,48,49 
 
The intricacies of DDIs and risk management in MM thus present a particular challenge to Choosing 
Wisely and guidelines in general.50,51 Research into MM-specific opportunities for Choosing Wisely is 
needed to determine which tests and treatments are unnecessary.52 Given the huge number and 
heterogeneity of MM clusters and DDIs,53,54,55 overuse research to develop five Choosing Wisely 
measures in MM could begin by prioritizing specific MM clusters (e.g., a top-five list of MM clusters). 
The aims would be to determine the scale and primary sources of overuse (e.g., over-precaution in risk 
management), understand moderating factors (e.g., differences in expertise and risk perception, 
stress, cognitive overload, patient anxiety and demands, attitudes toward different types of 
intervention),56,57,58,59,60 and develop and integrate recommendations into the management of these 
clusters. The potential impact on care value could be large, considering the high prevalence of MM. 
61,62,63  
 
Future developments and challenges 
 
Change in health policies and practices and public knowledge and expectations should be evidence-
based.64 The successes of Choosing Widely in different countries may give impetus to a more 
coordinated global initiative and effort. Thus, a number of factors might help to overcome engrained 
practices and to sustain acceptance and adoption of Choosing Wisely: A synthesis of the existing top 
five lists across participating countries and specialist fields may further promote good practice such 
that these are internationally accepted and adopted norms (i.e., quality goals to aim for), despite 
considerable heterogeneity of health care provision and policy across different countries. 
Multinational top five lists may serve to better patient outcomes and to reduce waste in a global effort. 
This may strengthen research on overuse.65 The scope of this research should be broadened to 
generate Choosing Wisely recommendations that align well with the everyday context of the diverse 
challenges encountered by physicians, patients and relatives in dealing with the intricacies of managing 
MM and polypharmacy. Prioritizing a top-five list of prevalent MM clusters might facilitate the 
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